Research graph
References from Risk of bradycardia and syncope associated with the use of cholinesterase inhibitors in patients with Alzheimer disease and related dementias: A systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
10.1016/s2468-2667(21)00249-8 · 2022 · External reference
Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia
10.1111/j.1532-5415.2011.03478.x · 2011 · External reference
Cardiac effect of cholinesterase inhibitors used in Alzheimer’s disease – from basic research to bedside
10.2174/1567205043332009 · 2004 · External reference
The elusive pathophysiology of neurally mediated syncope
10.1161/01.cir.102.23.2898 · 2000 · External reference
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study
10.1001/archinternmed.2009.43 · 2009 · External reference
A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs
10.1001/archinte.165.7.808 · 2005 · External reference
Unresolved reference
External reference
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group
10.1001/archinte.158.9.1021 · 1998 · External reference
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group
10.1212/wnl.50.1.136 · 1998 · External reference
Reporting of safety results in published reports of randomized controlled trials
10.1001/archinternmed.2009.306 · 2009 · External reference
Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials
10.1016/j.jclinepi.2008.08.005 · 2009 · External reference
Causes of syncope in patients with Alzheimer’s disease treated with donepezil
10.2165/00002512-200522080-00005 · 2005 · External reference
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer’s disease
10.1093/europace/eum148 · 2007 · External reference
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs new England healthcare system
10.1111/j.1532-5415.2009.02488.x · 2009 · External reference
Syncope with cholinesterase inhibitors
2011 · External reference
Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials
10.1111/j.1532-5415.2011.03450.x · 2011 · External reference
Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review
10.1111/jgs.15415 · 2018 · External reference
Adverse drug event profile associated with anti-dementia drugs: analysis of a spontaneous reporting database
2023 · External reference
Association of antidementia therapies with time to skilled nursing facility admission and cardiovascular events among elderly adults with Alzheimer disease
10.1001/jamanetworkopen.2019.0213 · 2019 · External reference
Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies
10.1517/14656566.2014.936848 · 2014 · External reference
Anti-dementia drugs: a descriptive study of the prescription pattern in Italy
10.1007/s10072-022-06586-8 · 2023 · External reference
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact
10.1186/s13195-023-01271-0 · 2023 · External reference
Alzheimer disease treatment with acetylcholinesterase inhibitors and incident age-related macular degeneration
10.1001/jamaophthalmol.2023.6014 · 2024 · External reference
Principle of rational prescribing and deprescribing in older adults with multiple chronic conditions
10.1177/2042098618791371 · 2018 · External reference
Rational deprescribing practices in elderly patients: an expert opinion
10.5005/jp-journals-10070-8072 · 2024 · External reference
A systematic review of clinical practice guidelines for Alzheimer’s disease and strategies for future advancements
10.1007/s40120-023-00504-6 · 2023 · External reference
Unresolved reference
External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Hypotension and syncope
2022 · External reference
Rayyan-a web and mobile app for systematic reviews
10.1186/s13643-016-0384-4 · 2016 · External reference
Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research
10.1136/bmjos-2020-100074 · 2021 · External reference
Unresolved reference
External reference
Quantifying publication bias in meta-analysis
10.1111/biom.12817 · 2018 · External reference
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
10.1136/bmj.d4002 · 2011 · External reference
Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice
10.1002/sim.7372 · 2017 · External reference
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson’s disease dementia patients
10.1002/mds.21997 · 2008 · External reference
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial
10.1161/01.str.0000091396.95360.e1 · 2003 · External reference
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease
10.2165/00023210-200620050-00005 · 2006 · External reference
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer’s disease
10.1002/gps.1746 · 2007 · External reference
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
10.1016/s1474-4422(08)70261-8 · 2009 · External reference
Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial
10.1111/jgs.14827 · 2017 · External reference
Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer’s disease
10.2165/00002512-200825020-00008 · 2008 · External reference
Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
10.1212/01.wnl.0000344650.95823.03 · 2009 · External reference
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
10.1186/1471-2377-11-57 · 2011 · External reference
Comparative cardiovascular safety of dementia medications: a cross-national study
10.1111/j.1532-5415.2012.04241.x · 2012 · External reference
A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease
10.1016/j.jamda.2015.08.019 · 2016 · External reference
Cardiac and blood pressure safety of transdermal rivastigmine in elderly patients with dementia with Lewy bodies
10.1097/wad.0000000000000401 · 2020 · External reference
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands
10.1016/j.amjopharm.2012.11.002 · 2012 · External reference
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
10.1212/wnl.57.3.481 · 2001 · External reference
A 24-week, randomized, controlled study to evaluate the tolerability, safety and efficacy of 2 different titration schemes of the rivastigmine patch in Japanese patients with mild to moderate Alzheimer’s disease
10.1159/000439269 · 2015 · External reference
Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study
10.1371/journal.pmed.1000157 · 2009 · External reference
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease
10.1007/s00228-005-0946-1 · 2005 · External reference
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
10.1177/1533317509333037 · 2009 · External reference
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
10.1212/wnl.57.3.489 · 2001 · External reference
Two galantamine titration regimens in patients switched from donepezil
10.1111/j.1600-0404.2011.01594.x · 2012 · External reference
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease
10.1002/gps.409 · 2001 · External reference
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
10.1212/wnl.54.12.2269 · 2000 · External reference
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis
10.1093/ageing/afad205 · 2023 · External reference
A risk-benefit assessment of dementia medications: systematic review of the evidence
10.1007/s40266-015-0266-9 · 2015 · External reference
Cognitive enhancers and treatments for Alzheimer’s disease
2008 · External reference
Pathophysiology and differential diagnosis of neurocardiogenic
10.1016/s0002-9149(99)00691-8 · 1999 · External reference
Syncope in the elderly
1997 · External reference
Fixed-effect vs random-effects models for meta-analysis: 3 points to consider
10.1177/21925682221110527 · 2022 · External reference
How to assess publication bias: funnel plot, trim-and-fill method and selection models
10.1136/eb-2013-101699 · 2014 · External reference
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects
10.1056/nejmoa067407 · 2007 · External reference
Understanding relative risk, odds ratio, and related terms: as simple as it can get
10.4088/jcp.15f10150 · 2015 · External reference
